Hansa Biopharma’s Phase 3 Study on Imlifidase: A Potential Game Changer in Kidney Transplantation

Hansa Biopharma ((SE:HNSA)) announced an update on their ongoing clinical study.

Hansa Biopharma’s recent clinical study, titled ‘An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC,’ aims to assess the effectiveness of imlifidase in improving kidney function in highly sensitized kidney transplant patients. The study’s significance lies in its potential to enhance transplant outcomes for patients with limited options due to high sensitization.

The intervention being tested is imlifidase, an enzyme that degrades immunoglobulin G, intended to facilitate successful kidney transplantation by reducing donor-specific antibodies. It is compared against the best available treatment, which includes various desensitization protocols or remaining on the waitlist for a more compatible organ.

The study employs a randomized, open-label, controlled, parallel intervention model with no masking. Its primary purpose is treatment, focusing on evaluating the estimated glomerular filtration rate (eGFR) 12 months post-randomization as a predictor of clinical benefit in patient survival.

The study began on October 14, 2021, and was completed with its last update submitted on July 15, 2025. These dates are crucial as they mark the study’s progression and the availability of updated data for analysis.

This update could influence Hansa Biopharma’s stock performance positively, as successful outcomes may boost investor confidence and position the company favorably against competitors in the kidney transplant market. The study’s completion and updates could attract investor attention, given the potential market for improved desensitization treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.